Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $34.95, for a total value of $6,990,000.00. Following the completion of the sale, the chief executive officer directly owned 1,613,063 shares in the company, valued at $56,376,551.85. This represents a 11.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Eric Venker also recently made the following trade(s):
- On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00.
- On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00.
Roivant Sciences Price Performance
ROIV opened at $34.52 on Friday. Roivant Sciences Ltd. has a 12 month low of $10.90 and a 12 month high of $37.00. The stock has a market capitalization of $24.83 billion, a P/E ratio of -57.53 and a beta of 1.11. The business has a 50 day simple moving average of $32.55 and a 200-day simple moving average of $29.02.
Institutional Investors Weigh In On Roivant Sciences
Analyst Ratings Changes
Several equities research analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. TD Cowen boosted their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Finally, Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $33.59.
View Our Latest Report on ROIV
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.
Featured Articles
- Five stocks we like better than Roivant Sciences
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
